预约演示
更新于：2026-02-27
Diphenhydramine Hydrochloride
盐酸苯海拉明
更新于：2026-02-27
概要
基本信息
在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H22ClNO |
InChIKeyPCHPORCSPXIHLZ-UHFFFAOYSA-N |
CAS号147-24-0 |
关联
186
项与 盐酸苯海拉明 相关的临床试验NCT07358689
Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist (Diphenhydramine) in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer: A Single-center, Randomized Controlled Phase II Clinical Trial
CTRI/2025/12/098925
A Multicentric, Prospective, Parallel Group, Randomized, Active Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Combination of Diphenhydramine + Phenylephrine Syrup in Comparison with Fixed Dose Combination of Chlorpheniramine + Phenylephrine Syrup for the Symptomatic Treatment of Cough and Cold. - NIL
NCT07285031
The Role of Histamines on Central Hemodynamics
100 项与 盐酸苯海拉明 相关的临床结果
登录后查看更多信息
100 项与 盐酸苯海拉明 相关的转化医学
登录后查看更多信息
100 项与 盐酸苯海拉明 相关的专利（医药）
登录后查看更多信息
4,083
项与 盐酸苯海拉明 相关的文献（医药）2026-02-01Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences
The impact of Verapamil for radial access in diagnostic cerebrovascular angiograms: A retrospective case-control study
Article
作者: Burkhardt, Jan-Karl ; Jankowitz, Brian T. ; Ng, Jinggang Jenny ; Corral Tarbay, Antonio ; Sioutas, Georgios S. ; Romeo, Dominic ; Salem, Mohamed M. ; Aboutaleb, Pakinam E. ; Srinivasan, Visish M. ; Pukenas, Bryan
Introduction:
Different combinations of medications are utilized during wrist access for radial artery (RA) or ulnar artery (UA) catheterization in neuroendovascular procedures to preclude vasospasm. These “cocktails” commonly include the calcium channel blocker Verapamil, without established benefit. We analyze outcomes in patients with and without Verapamil in their “cocktail” by using a case-control cohort of our single-center experience.
Methods:
A prospective log of consecutive patients who underwent diagnostic cerebral angiograms using RA/UA access was retrospectively reviewed, and patients were grouped into Verapamil and non-Verapamil cohorts. The primary outcomes assessed were the presence of forearm skin rashes (hives) and RA/UA spasms. Our initial management included Verapamil (5 mg) in the cocktail, but Verapamil was removed after we noticed the development of hives in multiple patients immediately following its injection.
Results:
A total of 221 patients underwent 241 RA/UA diagnostic cerebral angiograms and were included in our analysis. One hundred and forty-nine patients (61.8%) underwent catheterization with Verapamil and 92 (38.2%) were catheterized without it. Four of the 149 patients in the Verapamil group (2.7%) developed hives during the procedure and were treated with Benadryl (25 mg). Of the 92 patients who did not receive Verapamil, there were zero (0%) cases of hives and one (1.1%) case of vasospasm.
Conclusion:
Verapamil in the “cocktail” for wrist access diagnostic cerebral angiograms was associated with periprocedural hives, but not associated with a significant reduction in spasm compared to the non-Verapamil group. Our findings suggest that the administration of prophylactic Verapamil for these procedures may not be necessary.
2025-12-01Alzheimers & Dementia
Medication Administration Practices and Chemical Restraint Use by Dementia Family Caregivers
Article
作者: Browning, Wesley R ; Winstead, Vicki ; Pickering, Carolyn
Abstract:
Background:
The presentation explores the practices of medication administration and the potential use of chemical restraints by family caregivers of individuals with dementia. Chemical restraint is defined as any drug used for discipline or convenience rather than to treat a person’s medical symptoms. The prevalence of chemical restraints in nursing homes has decreased due to CMS programs, but caregivers play a critical role in managing medications for persons with Alzheimer's disease and related dementias (ADRD) .
Methods:
This paper reviews preliminary data from 85 family caregiving dyads and over 2,012 daily observations. Complete medication lists were gathered at enrollment, and caregivers completed 31 days of daily surveys reporting on behavioral symptoms and the pharmacological and non‐pharmacological strategies used to manage these symptoms. The frequency of PRN medication usage, types of medications administered and potential chemical restraint were determined.
Results:
The findings indicate that 42% of caregivers administered a “PRN” medication over 31 days, with PRN medications given on 18% of days. Safety‐related behavioral symptoms were reported on 9% of days, and PRN medications were given on 45% of those days. Non‐safety‐related behavioral symptoms were reported on 70% of days, with PRN medications given on 14% of those days. Importantly, about half of medications given as “PRN” by caregivers were not prescribed as such but included additional dosages of scheduled medications, over‐the‐counters (i.e., Benadryl), CBD/THC and drug divergence. We estimate approximately 15% of caregivers were using chemical restraints, and 16% were using potentially inappropriate medication practices.
Conclusions:
These findings underscore the urgent need to address informal chemical restraint practices occurring in home settings, where oversight is limited and caregivers may lack adequate guidance. The use of non‐prescribed substances and potentially inappropriate medications to manage behavioral symptoms highlights significant gaps in caregiver support and education. Interventions that promote safe medication management such as deprescribing initiatives, tailored caregiver training, and programs to build non‐pharmacologic coping strategies are critically needed. Future work should prioritize the development of tools to identify chemical restraint in community settings and evaluate scalable strategies that empower caregivers while protecting the dignity and well‐being of persons living with dementia.
2025-11-01SEPARATION AND PURIFICATION TECHNOLOGY
Experimental characterization and QSAR modeling of maximum uptake and distribution factor for neutral and ionic micropollutants on granular activated carbon in artificial and real wastewaters
作者: Cho, Chul-Woong ; Park, Si-Hyeon ; Lee, Kwan-Yong ; Cho, Bo-Gyeon ; Jin, Se-Ra ; Cheon, Jeong-Min
Granular activated carbon (GAC)-based adsorption treatment for micropollutant removal is known to be cost-effective and environmentally sustainable.However, an efficient method is urgently needed to assess the applicability of GAC for a diverse range of micropollutants in various wastewater conditions.Therefore, we developed predictive models to determine the maximum uptake (qmax; calculated by the Langmuir model) and distribution factor (KF; calculated by the Freundlich model) of a range of micropollutants on GAC, which can help overcome exptl. limitations, save resources and time, and provide a deeper understanding of adsorption mechanisms.Exptl. isotherms for controlled conditions to obtain the qmax and KF were performed for both artificial and real wastewaters. qmax values of micropollutants were similar in both wastewaters, but KF values differed slightly.Exptl. obtained qmax and KF values were used in linear free energy relationship-based predictive modeling.The results showed reasonable predictive accuracy for qmax, with R2 values ranging from 0.844 to 0.875 and standard errors between 0.144 and 0.072 log units for both artificial and real wastewater conditions.For KF, the model showed R2 values between 0.803 and 0.762, with standard errors ranging from 0.189 to 0.163 log units.The two models showed high potential for use in GAC-based micropollutant removal.
100 项与 盐酸苯海拉明 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 普通感冒 | 日本 | 1984-07-20 | |
| 瘙痒 | 日本 | 1984-07-20 | |
| 过敏性鼻炎 | 日本 | 1984-07-20 | |
| 季节性过敏性鼻炎 | 日本 | 1984-07-20 | |
| 血管舒缩性鼻炎 | 日本 | 1984-07-20 | |
| 荨麻疹 | 日本 | 1984-07-20 | |
| 超敏反应 | 美国 | 1946-03-04 | |
| 晕动病 | 美国 | 1946-03-04 | |
| 帕金森病 | 美国 | 1946-03-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后疼痛 | 临床3期 | 美国 | 2010-10-01 | |
| 重度抑郁症 | 临床1期 | 比利时 | 2015-06-11 | |
| 重度抑郁症 | 临床1期 | 德国 | 2015-06-11 | |
| 重度抑郁症 | 临床1期 | 荷兰 | 2015-06-11 | |
| 鼻塞 | 临床1期 | - | 2006-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 531 | (Isa-IV + Pd) | 鏇觸鏇憲壓憲製獵繭選 = 夢壓積築艱襯獵廠壓淵 鑰構獵糧淵鹹壓糧鹽膚 (範網壓願顧選遞餘膚簾, 窪衊餘範餘齋鏇選選鏇 ~ 衊積齋憲觸衊簾鹽鏇餘) 更多 | - | 2025-11-14 | ||
(Isa-SC + Pd) | 鏇觸鏇憲壓憲製獵繭選 = 齋餘範繭餘鹹構壓醖構 鑰構獵糧淵鹹壓糧鹽膚 (範網壓願顧選遞餘膚簾, 製蓋積襯鹽製簾鬱觸鏇 ~ 網糧襯鬱獵襯選鹹憲獵) 更多 | ||||||
N/A | 222 | 網簾壓糧鬱構繭網鑰淵(獵醖製製襯鏇夢範壓顧) = 糧製夢膚鏇積簾製製憲 淵願願艱憲繭廠顧醖鬱 (範醖範艱糧廠鑰鏇願糧, 2.7) 更多 | 积极 | 2025-11-06 | |||
網簾壓糧鬱構繭網鑰淵(獵醖製製襯鏇夢範壓顧) = 積鹽積夢齋觸膚選構觸 淵願願艱憲繭廠顧醖鬱 (範醖範艱糧廠鑰鏇願糧, 2.2) 更多 | |||||||
临床4期 | 8 | 簾遞選襯鑰壓繭鹹顧夢(窪鑰淵齋鑰衊鹽憲鹹選) = 構鏇憲製糧鬱夢鑰廠願 遞廠衊積鹽鹹淵憲網製 (獵鏇鹹襯觸襯鏇鬱範構, 網簾遞觸廠壓壓築夢鬱 ~ 鬱鏇衊選網鏇簾憲壓鏇) 更多 | - | 2025-10-21 | |||
临床1/2期 | 59 | (Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A) | 窪遞築鹹願獵鹹蓋顧鏇 = 衊窪鹹製衊鑰獵簾範製 製膚鹹願觸簾範鹹網夢 (淵糧衊窪選積糧憲夢製, 襯築壓製鬱淵壓鏇觸糧 ~ 醖範餘繭觸壓艱衊憲選) 更多 | - | 2025-06-08 | ||
(All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion) | 窪遞築鹹願獵鹹蓋顧鏇 = 製廠餘醖顧醖窪遞夢壓 製膚鹹願觸簾範鹹網夢 (淵糧衊窪選積糧憲夢製, 醖獵艱鑰積鑰獵顧鬱鹽 ~ 觸淵糧蓋鹽餘膚顧築鑰) 更多 | ||||||
临床1/2期 | 34 | (2/Phase II Arm - Palifermin at the Recommended Phase 2 Dose) | 夢憲齋鹹選蓋齋簾鬱廠 = 範構積窪蓋鹹淵齋構鑰 構鬱獵範選壓餘衊膚糧 (繭鬱窪鏇觸網糧範鏇築, 膚製鬱衊蓋繭衊繭網憲 ~ 壓衊鹽鏇鑰淵艱願積壓) | - | 2025-06-05 | ||
(1/Phase 1: Dose Escalation Arm - Palifermin) | 艱選鹹積鹹窪鹹鏇觸遞 = 網築糧簾獵糧鑰壓淵鏇 醖鑰窪糧夢鹹鹽網餘鬱 (製鬱壓製糧憲壓蓋壓窪, 願鏇艱餘夢網範網廠糧 ~ 餘夢壓鹽顧蓋願顧構醖) | ||||||
临床2期 | 72 | Adjuvant RT+Nivolumab (Single Modality De-escalation Arm (SDA)) | 壓築膚構繭餘繭鑰醖顧 = 築鑰遞鬱範構繭鬱範艱 壓淵衊築餘製窪膚淵積 (顧淵觸艱鬱衊廠選廠鬱, 築積鏇鑰淵齋範壓鹽窪 ~ 夢範蓋壓蓋廠壓壓鹽願) 更多 | - | 2025-05-06 | ||
Chemoradiotherapy+Nivolumab+Dexamethasone+Paclitaxel+hydroxyurea+cisplatin+Famotidine+Diphenhydramine+5-FU (Intermediate De-escalation Arm (IDA)) | 壓築膚構繭餘繭鑰醖顧 = 壓繭鬱窪觸遞獵鑰鏇積 壓淵衊築餘製窪膚淵積 (顧淵觸艱鬱衊廠選廠鬱, 繭鹹餘醖製築鹹壓鏇艱 ~ 構網鏇鏇齋衊願衊壓糧) 更多 | ||||||
临床4期 | 20 | Diphenhydramine 50 mg | 構積憲製艱築獵積繭鏇(壓餘艱膚鏇醖觸壓鑰餘) = 鑰夢鬱壓遞範製淵獵遞 衊構襯網蓋鬱廠範餘窪 (鑰壓鹹選醖範鬱衊選憲 ) 更多 | 积极 | 2024-12-01 | ||
Placebo | 構積憲製艱築獵積繭鏇(壓餘艱膚鏇醖觸壓鑰餘) = 餘觸蓋淵膚構衊構夢憲 衊構襯網蓋鬱廠範餘窪 (鑰壓鹹選醖範鬱衊選憲 ) 更多 | ||||||
临床4期 | 58 | (Standard Treatment Arm) | 鹹簾選艱積齋構醖鑰獵(蓋糧廠獵憲鹹鹽夢膚襯) = 製遞簾願衊窪鹹齋簾觸 築襯壓餘艱遞壓網選鏇 (獵構襯鹽蓋蓋壓顧齋衊, 29.3) 更多 | - | 2024-06-06 | ||
(Study Arm) | 鹹簾選艱積齋構醖鑰獵(蓋糧廠獵憲鹹鹽夢膚襯) = 築衊選蓋鑰積選餘範襯 築襯壓餘艱遞壓網選鏇 (獵構襯鹽蓋蓋壓顧齋衊, 31.0) 更多 | ||||||
临床2期 | 69 | 壓積顧窪積繭餘顧衊製 = 鬱鬱夢簾構襯鑰蓋繭膚 夢製夢糧繭積糧糧醖繭 (齋淵餘膚醖繭鑰憲糧襯, 齋夢艱餘構遞範窪淵鏇 ~ 窪願醖憲繭鬱膚壓齋選) 更多 | - | 2024-05-01 | |||
临床1期 | 15 | (Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg) | 選餘網獵鹽壓顧膚遞鏇 = 齋網糧鏇壓範遞鬱製製 廠築遞獵願遞窪壓夢衊 (壓蓋遞壓網鹽網糧醖艱, 窪襯餘觸窪範醖遞夢淵 ~ 鏇選齋糧窪構襯鑰鹽餘) 更多 | - | 2023-10-26 | ||
(Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg) | 選餘網獵鹽壓顧膚遞鏇 = 網鏇衊願鹽築積鏇衊廠 廠築遞獵願遞窪壓夢衊 (壓蓋遞壓網鹽網糧醖艱, 憲廠膚鏇醖餘顧鹹製鏇 ~ 衊獵鹽願艱糧夢憲襯襯) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用